# GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

> **NCT04601402** · PHASE1 · COMPLETED · sponsor: **Genome & Company** · enrollment: 11 (actual)

## Conditions studied

- Solid Tumor
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma

## Interventions

- **DRUG:** GEN-001
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04601402
- **Lead sponsor:** Genome & Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2023-01-11
- **Final completion:** 2023-01-11
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04601402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04601402, "GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04601402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*